Abstract: Although most breast cancers in BRCA1 mutation carriers are estrogen receptor negative (ERÀ) with a basal-like phenotype, up to one third are ER positive (ER+). Little is known about the characteristics of this subgroup. To address this, we compared histologic and immunophenotypic features of 60 BRCA1-related ER+ breast cancers with those of 85 BRCA1-related ER À cancers and 174 matched ER+ sporadic cancers. ER+ BRCA1-related cancers were significantly less likely than ER À BRCA1-related cancers to be of pure invasive ductal type (P < 0.001) and to be of histologic grade 3 (P < 0.001), and less frequently to have a high mitotic rate (P < 0.001), pushing (or unknown) margins (P < 0.001), a moderate/marked lymphocytic infiltrate (P = 0.003), or geographic necrosis/fibrotic focus (P < 0.001). In addition, ER+ BRCA1-related cancers less often expressed CK5/6 (P < 0.0001), CK14 (P < 0.0001), and epidermal growth factor receptor (P < 0.0001) and more often expressed progesterone receptor (P < 0.0001). In contrast, when compared with ER+ sporadic cancers, ER+ BRCA1-related cancers were significantly more often of invasive ductal type (P = 0.005) and of histologic grade 3 (P = 0.006), more frequently had a high mitotic rate (P = 0.0003), and were more often CK14+ (P = 0.03). On unsupervised cluster analysis, some ER+ BRCA1 cancers clustered more closely with sporadic ER+ cancers, whereas others clustered more closely with ERÀ BRCA1-related cancers. Nuclear expression levels of poly(ADP) ribose polymerase 1 in ER+ BRCA1-related cancers were similar to those in ERÀ BRCA1-related cancers but significantly higher than in ER+ sporadic cancers. We conclude that ER+ BRCA1-related breast cancers show several morphologic and immunophenotypic differences from ER+ sporadic breast cancers as well as some similarities to ERÀ BRCA1-related cancers.
M
ost invasive breast cancers arising in women with germline BRCA1 mutations are estrogen receptor negative (ER À) and progesterone receptor negative (PR À) and are negative for HER2 protein overexpression and gene amplification (triple negative). 3, 6, 8, 11, 15, 20, 22, 25 In addition, these tumors have distinctive morphologic features and are most often high-grade invasive ductal carcinomas that frequently have pushing or circumscribed borders with a marked lymphocytic infiltrate, fibrotic focus, and/or geographic necrosis. 1, 13, 22 Further, they commonly express biomarkers associated with a "basal phenotype" including CK5/6, CK14, and epidermal growth factor receptor (EGFR), and most of these tumors cluster within the "basallike" group in gene expression profiling studies. 2, 8, 12, 14 Although ERÀ breast cancers arising in BRCA1 mutation carriers have been well characterized, between 10% and 36% of BRCA1 mutation-related invasive breast cancers are, in fact, ER+. 3, 10, 15, 18, 25 Little is known about the clinical risk factors for ER+ BRCA1 breast cancers or about their histologic, immunophenotypic, or molecular characteristics. In a prior analysis, we documented, for the first time, the clinical risk factors for ER+ BRCA1 breast cancers and characterized some of their basic histologic features. 24 In a subsequent analysis, we showed that over 80% of ER+ BRCA1 breast cancers exhibited loss of the wild-type BRCA1 allele indicating that these tumors are, in fact, mutation-related and suggesting that therapeutic agents designed to exploit BRCA1 deficiency may be effective in ER+ cancers that develop in this population. 23 The purpose of the present study was to (1) characterize in greater detail the histologic features of ER+ BRCA1 breast cancers; (2) compare the immunophenotype of these tumors to that of ERÀ BRCA1 breast cancers and to matched sporadic ER+ breast cancers using unsupervised hierarchical cluster analysis; and (3) assess the levels of poly(ADP) ribose polymerase 1 (PARP-1) in these tumors to evaluate whether patients with ER+ BRCA1 breast cancers could potentially benefit from drugs that exploit BRCA1 deficiency (ie, PARP inhibitors).
MATERIALS AND METHODS

Patient Selection
Through the Cancer Risk and Prevention Programs at Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital/Dana Farber Cancer Institute, and North Shore Medical Center, we retrospectively identified 178 invasive breast cancers that arose in women with germline BRCA1 mutations. Pathologic material, including hematoxylin and eosin-stained sections and/or paraffin blocks, was available for analysis for 145 of these cancers (85 ER À and 60 ER+). Any cases diagnosed before 1986 did not have obtainable pathologic material. In addition, due to a major research focus on triple-negative breast cancers at the participating institutions, the pathologic material of some of the ER-negative cancers was not available for this study.
For the case-control analysis, sporadic ER+ invasive breast cancers (controls) were identified through the BIDMC tumor registry. Invasive ER+ breast cancer arising in women with no family history of breast or ovarian cancer were matched on age and year of diagnosis (within 3 y) to the ER+ cancers arising in patients with a germline BRCA1 mutation (cases). Genetic testing records at BIDMC were reviewed to exclude potential BRCA1 or BRCA2 mutations among patients in the control group. Three controls were matched to each case with the exception of 6 cases for which only 2 controls could be identified.
Data Collection
ER, PR, and HER2 status for each tumor was abstracted from the original pathology reports. When the ER status for BRCA1 mutation-related tumors was missing from the pathology report or when ER was initially reported as "weak" or "faint," surface recuts were made from the paraffin blocks and were immunostained for ER (rabbit monoclonal antibody SP1; Neomarkers, Fremont, CA). 
Pathology Review
Tissue Microarray Construction and Biomarker Analysis
Paraffin blocks were available for 74 ER À BRCA1-related cancers, 53 ER+ BRCA1-related cancers, and 153 ER+ sporadic cancers. Tissue microarrays were constructed from the tumors in these blocks by obtaining three 0.6-cm cores from each block and inserting them into recipient blocks.
Sections cut from the tissue microarrays were immunostained using mouse monoclonal antibodies for luminal cytokeratins (CK7/8, CK18, CK19), basal cytokeratins (CK5/6, CK14), EGFR, p53, PR, HER2, and PARP-1 ( Table 1) . For all cytokeratins, EGFR, and PR, staining was scored as either negative (when there was no tumor cell staining), positive with <10% of tumor cells positive, or positive with 10% or more of tumor cells positive. p53 staining was scored as negative (when there was no nuclear staining) or positive on the basis of distribution (focal or diffuse) and intensity (weak or strong) of staining. PARP-1 staining was scored for intensity and distribution using the Allred scoring system.
Statistical Analysis
Pathologic features of ER+ and ER À BRCA1-related cancers and of ER+ BRCA1-related and ER+ sporadic cancers were compared using w 2 or Fisher exact tests as appropriate.
Immunostaining results for luminal cytokeratins (CK7/8, CK18, CK19), basal cytokeratins (CK5/6, CK14), EGFR, p53, PR, and HER2 between groups were compared using w 2 or Fisher exact tests as appropriate and by unsupervised hierarchical clustering using Cluster and Treeview programs. 4 PARP-1 immunostaining results between groups were compared using the KruskalWallis test.
This study was approved by the institutional review boards of Dana Farber Harvard Cancer Center and North Shore Medical Center. Table 2 compares the pathologic features of the 60 ER+ and 85 ER À BRCA1 breast cancers. ER+ BRCA1 breast cancers were found to be significantly less likely than ER À BRCA1-related cancers to be of pure invasive ductal type (P < 0.001), to be of histologic grade 3 (P < 0.001), to have a high mitotic rate (> 10 mitoses per 10 HPF) (P < 0.001), to have pushing (or unknown) margins (P < 0.001), to have a moderate/marked lymphocytic infiltrate (P = 0.003), or to have geographic necrosis and/ or a fibrotic focus (P < 0.001). Table 3 compares the expression of biomarkers in ER+ and ER À BRCA1 breast cancers. The ER+ BRCA1-related cancers were less likely than ER À BRCA1-related cancers to express CK5/6 (P < 0.0001), CK14 (P < 0.0001), or EGFR (P < 0.0001). In addition, ER+ BRCA1-related cancers were significantly more likely to express PR compared with ER À BRCA1-related cancers (P < 0.0001). There was no significant difference in p53 expression between these 2 groups.
RESULTS
Comparison of ER À and ER+ BRCA1 Mutationrelated Breast Cancers
Comparison of ER+ BRCA1 Mutation-related Breast Cancers and Sporadic ER+ Breast Cancers
The pathologic features of the 60 ER+ BRCA1-related cancer cases and 174 ER+ sporadic cancers are compared in Table 4 . ER+ BRCA1-related cancers were significantly more likely than ER+ sporadic cancers to be of pure invasive ductal type (P = 0.005), to be of histologic grade 3 (P = 0.006), and to have a high mitotic rate (> 10 mitoses per 10 HPF) (P = 0.003).
Biomarker expressions in ER+ BRCA1-related cancers and ER+ sporadic cancers are compared in Table 5 . The ER+ BRCA1-related cancers were 4 times more likely to express CK14 (P = 0.03) than ER+ sporadic cancers. Although a higher percentage of ER+ BRCA1-related cancers compared with ER+ sporadic cancers expressed p53 and the basal markers CK5/6 and EGFR, the differences did not reach statistical significance. On unsupervised cluster analysis 5 using the basal biomarkers studied (CK5/6, CK14, and EGFR), some ER+ BRCA1-related cancers clustered more closely with ER À BRCA1-related cancers than with other ER+ BRCA1-related cancers and ER+ sporadic cancers. However, given that the significant differences among the tumor types were related to their immunostaining patterns of the basal markers, another unsupervised cluster analysis was performed, which excluded ER status from the clustering algorithm (Fig. 1) . In this analysis, 12 ER+ BRCA1-related cancers clustered more closely with the ER À BRCA1-related cancers than with other ER+ BRCA1-related cancers and ER+ sporadic breast cancers. Of interest, loss of the wild-type BRCA1 allele was found in all 10 of these 12 tumors for which information regarding loss of wild-type BRCA1 was available. 23 
PARP-1 Expression in ER+ BRCA1 Mutationrelated Cancers, ERÀ BRCA1 Mutation-related Cancers, and ER+ Sporadic Cancers
Nuclear PARP-1 expression by immunohistochemistry was evaluable in 48 ER+ BRCA1-related cancers, 70 ERÀ BRCA1-related cancers, and 141 ER+ sporadic breast cancers. Table 6 shows the distribution of Allred Scores for PARP-1 expression in these 3 groups. ER+ BRCA1-related cancers were not significantly different from ERÀ BRCA1-related cancers with respect to their PARP-1 staining intensity and distribution (P = 0.45). In contrast, a significantly higher percentage of ER+ BRCA1-related cancers showed strong and diffuse PARP-1 staining, and a significantly lower percentage of ER+ BRCA1-related cancers were negative for PARP-1 expression when compared with the matched ER+ sporadic breast cancers (P = 0.002) (Fig. 2) .
DISCUSSION
The results of this study extend our prior, preliminary observations regarding the constellation of histologic features of ER+ breast cancers arising in women with BRCA1 germline mutations 24 and confirm that these tumors as a group show several key morphologic and immunophenotypic differences from ER+ sporadic breast cancers. Further, using unsupervised hierarchical cluster analysis we found that a subset of ER+ BRCA1-related cancers cluster more closely with ER À BRCA1-related cancers than with ER+ sporadic breast cancers and that The dendrogram (top) shows the degree of association between tumor samples, with short branches denoting a higher degree of similarity. Most ER+ BRCA1-related cancers cluster with ER+ sporadic cancers. However, several of the ER+ BRCA1-related cancers cluster tightly with a group of ERÀ BRCA1-related cancers (left side). most of the tumors in this subset show loss of the wild-type BRCA1 allele. 23 Finally, we found that ER+ BRCA1-related cancers demonstrated levels of nuclear PARP-1 expression that were similar to those seen in ER À BRCA1-related cancers and significantly higher than those seen in sporadic ER+ breast cancers. Taken together, these findings support the view that most ER+ breast cancers arising in women with germline BRCA1 mutations are causally related to the mutation and do not simply represent sporadic ER+ breast cancers arising coincidentally in women harboring these mutations. When compared with ER À BRCA1-related breast cancers, ER+ BRCA1-related cancers were less likely to have a high mitotic rate, pushing margins, prominent lymphocytic infiltrate, and geographic necrosis and/or a fibrotic focus and less often expressed CK5/6, CK14, and EGFR. Although these observations could lead to the speculation that the ER+ cancers in these patients simply represent sporadic ER+ breast cancers arising in women with germline BRCA1 mutations, several lines of evidence do not support this view. First, as a group the ER+ BRCA1-related breast cancers in this series showed several significant differences from a matched population of sporadic ER+ invasive breast cancers. In particular, the ER+ BRCA1-related cancers were more likely than sporadic ER+ cancers to be of invasive ductal type, to be of histologic grade 3, and have a high mitotic rate. In addition, these tumors expressed the basal marker CK14 four times more frequently than the ER+ sporadic breast cancers. Further, using unsupervised hierarchical cluster analysis of the basal markers, we found that 12 of the ER+ BRCA1-related cancers clustered more closely with the ER À BRCA1 group than with other ER+ BRCA1-related cancers or ER+ sporadic cancers. Ten of these tumors were high-grade invasive ductal carcinomas, and the other 2 were invasive ductal carcinomas combined with another subtype (lobular in one, mucinous in the other). Of 10 tumors evaluated for loss of the wild-type BRCA1 allele among these 12 cases, all showed loss of that allele. 23 Finally, nuclear PARP-1 expression levels in ER+ BRCA1-related cancers were similar to those in ER À BRCA1-related cancers and significantly higher than in sporadic ER+ breast cancers. Similar results were recently reported by Ozretic et al. 19 These findings strongly suggest that the majority, if not all, of the ER+ cancers that occur in women with germline BRCA1 mutations are causally related to the mutation. These results are consistent with prior data showing that 81% of ER+ BRCA1-related cancers exhibit loss of the BRCA1 wildtype allele. 23 Some authors have suggested that ER negativity is intrinsic to, and reflects the cell of origin of, BRCA1-related breast cancers. 7 This theory has been supported in vitro by the work of Hosey et al 9 who showed that transfection of the wild-type BRCA1 gene into an ER À breast cancer cell line homozygous for the BRCA1 mutation restored ER production and that knockdown of BRCA1 expression in ER+ cell lines resulted in cessation of ER production. Furthermore, it has been suggested that BRCA1 may be required for the differentiation of ER À stem/progenitor cells into ER+ luminal cells. 17 This model, however, fails to account for the origin of ER+ BRCA1-related breast cancers. More recently it has been proposed that ER+ BRCA1-related breast cancers may originate from a luminal progenitor cell consistent with the finding of an expansion of a luminal progenitor population containing both ER+ and ERÀ cells in preneoplastic breast tissue of women with germline BRCA1 mutations. 16 Previous studies have found basal cytokeratin expression in triple-negative breast cancers to be a good predictor of BRCA1 mutation status. 8, 21 Although we found that ER+ BRCA1-related breast cancers were significantly more likely to express CK14 than ER+ sporadic cancers, it is noteworthy that only 12 of the ER+ BRCA1-related cancers clustered with the ER À BRCA1-related cancers on cluster analysis, the majority clustering with ER+ sporadic cancers. Incorporating histologic and pathologic features as well as the results of nuclear PARP-1 staining might further distinguish ER+ mutation-related and sporadic breast cancers from each other. In addition, as ERÀ and ER+ BRCA1-related breast cancers may originate from a common early luminal progenitor cell, staining for markers that distinguish this from a more differentiated luminal progenitor cell (eg, CD49f, EpCAM, CD24, and CD133) may help to distinguish ER+ BRCA1-related from sporadic ER+ breast cancers. 16 The results of this study have potentially important clinical implications. The finding that ER+ BRCA1-related breast cancers are as a group morphologically and immunophenotypically different compared with sporadic ER+ breast cancers provides important information regarding the therapeutic approach to these cancers. The fact that ER+ BRCA1-related breast cancers are indistinguishable from ER À BRCA1-related cancers in their nuclear expression of PARP-1 yet demonstrate significantly higher levels of PARP-1 expression compared with sporadic cancers suggests that ER+ BRCA1-related breast cancers might respond well to drugs that exploit BRCA1 deficiency (ie, PARP inhibitors). ER status often guides therapy for breast cancer. However, certain biological markers (eg, HER2) provide an opportunity for effective treatment independent of ER status. The loss of functional BRCA1 and, therefore, effective homologous recombination, may be reflected in this nuclear PARP-1 staining, which can be used to identify these breast cancers, both ERÀ and ER+, that may respond to therapeutic agents that target this biological defect.
